(310) Conventional vs PEG-modified PLGA nanoparticles for sodium channel blockade in neuropathic pain

Introduction: Neuropathic pain involves burning or shooting sensations triggered by non-noxious stimuli (1). Limited drug efficacy, addiction, and overdose hamper current therapies. To address these issues, we developed a controlled delivery system for BIII 890 CL, a novel sodium ion channel blocker targeting chronic neuropathic pain. PLGA nanoparticles enable efficient encapsulation and targeted delivery but face hydrophobicity and opsonization challenges (2). PEG modification shields carriers and enhances permeability. This study assess PLGA formulations with and without PEG.